Aurinia Pharmaceuticals Inc.

AUPHSEC EDGAR

Pharmaceutical PreparationsCIK: 1600620

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$175.5M	$134.0M	$45.6M	$50.1M	$318.0K
Cost of Revenue	$14.1M	$5.7M	$1.1M	$0.00	$0.00
Research and Development Expense	$49.6M	$45.0M	$51.1M	$50.3M	$52.9M
Selling, General and Administrative Expense	—	—	$173.5M	$97.3M	$22.3M
Operating Expenses	$63.6M	$64.0M	$59.5M	$51.5M	$27.1M
Operating Income (Loss)	-$91.7M	-$111.5M	-$180.7M	-$104.3M	-$90.9M
Interest Expense	—	—	$0.00	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$550.6M	$548.1M	$470.9M	$543.4M	$463.7M
Assets, Current	$446.6M	$424.8M	$442.5M	$513.3M	$419.4M
Cash and Cash Equivalents, at Carrying Value	$48.8M	$94.1M	$231.6M	$272.4M	$306.0M
Inventory, Net	$39.2M	$39.7M	$24.8M	$19.3M	$13.9M
Liabilities	$173.2M	$170.1M	$65.4M	$64.3M	$55.9M
Liabilities, Current	$97.8M	$77.2M	$46.1M	$40.6M	$32.0M
Accounts Payable, Current	$5.2M	$4.3M	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$33.5M	-$79.5M	-$157.7M	-$69.9M	-$63.6M
Net Cash Provided by (Used in) Investing Activities	-$6.7M	-$60.6M	-$103.9M	-$158.2M	$7.8M
Net Cash Provided by (Used in) Financing Activities	-$5.1M	$2.4M	$221.1M	$194.4M	$243.9M
Payments for Capital Improvements	—	—	—	$21.0M	$21.0M
Payments for Repurchase of Common Stock	$0.00	$0.00	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)